Mixue Xie

Qingchun Road 79#
Hangzhou, 310003, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 32 publications

The PI3K/AKT signaling networks in cancer glucose metabolism: mechanisms and therapeutic implications.

The PI3K/AKT signaling networks in cancer glucose metabolism: mechanisms and therapeutic implications.

Journal: Translational oncology

Published: March 17, 2026

Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.

Finite-Duration Venetoclax/Azacitidine Followed by Umbilical Cord Blood Infusion Improves Outcomes in Frail Elderly Patients With Untreated Acute Myeloid Leukemia-A Pilot Study.

Journal: Cancer medicine

Published: December 13, 2025

Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trial.

Glofitamab combined with tislelizumab in relapsed/refractory diffuse large B-cell lymphoma: a single-center pilot trial.

Journal: Blood cancer journal

Published: June 12, 2025

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block.

Journal: Blood cancer journal

Published: November 18, 2024

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.

Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China.

Journal: Blood

Published: July 15, 2024

Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.

Dasatinib plus prednisone as induction and consolidation for adults with Ph-positive acute lymphoblastic leukaemia: A single-arm, multicentre, phase 2 trial.

Journal: British journal of haematology

Published: April 18, 2023

Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Chemotherapy with the use of next-generation tyrosine kinase inhibitors based on measurable residual disease has the potential to avoid hematopoietic stem cell transplantation in treatment for adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Journal: Cancer

Published: September 25, 2022

Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Cancer cell membrane-wrapped nanoparticles for cancer immunotherapy: A review of current developments.

Journal: Frontiers in immunology

Published: June 20, 2022

The favorable prognostic value of the loss of sex chromosomes in patients with t(8;21) acute myeloid leukemia: an exploratory study.

The favorable prognostic value of the loss of sex chromosomes in patients with t(8;21) acute myeloid leukemia: an exploratory study.

Journal: Hematology (Amsterdam, Netherlands)

Published: April 12, 2022

Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.

Distinct outcomes, ABL1 mutation profile, and transcriptome features between p190 and p210 transcripts in adult Philadelphia-positive acute lymphoblastic leukemia in the TKI era.

Journal: Experimental hematology & oncology

Published: November 11, 2021

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.

Treatment-Related Adverse Events of Chimeric Antigen Receptor T-Cell (CAR T) in Clinical Trials: A Systematic Review and Meta-Analysis.

Journal: Cancers

Published: June 24, 2021

Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma.

Significance of initial, interim and end-of-therapy 18F-FDG PET/CT for predicting transformation risk in follicular lymphoma.

Journal: Cancer cell international

Published: May 09, 2021

Showing 1-12 of 32

Last Updated: 09/26/2026